Literature DB >> 24943201

Review of preclinical studies on treatment of mucositis and associated pain.

C T Viet1, P M Corby2, A Akinwande3, B L Schmidt4.   

Abstract

Oral mucositis is a significant problem in cancer patients treated with radiation or chemotherapy, often hindering definitive cancer treatment. For patients with oral mucositis, pain is the most distressing symptom, leading to loss of orofacial function and poor quality of life. While oral mucositis has been well-described, its pathophysiology is poorly understood. Oral health professionals treating patients with mucositis have almost no effective therapies to treat or prevent oral mucositis. The purpose of this review is to (1) describe the current preclinical models of oral mucositis and their contribution to the understanding of mucositis pathophysiology, (2) explore preclinical studies on therapies targeting mucositis and discuss the clinical trials that have resulted from these preclinical studies, and (3) describe the proposed pathophysiology of oral mucositis pain and preclinical modeling of oral mucositis pain. © International & American Associations for Dental Research.

Entities:  

Keywords:  cancer complications; cancer symptoms; mucositis models; mucositis treatment; oral pain; stomatitis

Mesh:

Substances:

Year:  2014        PMID: 24943201      PMCID: PMC4213248          DOI: 10.1177/0022034514540174

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  61 in total

1.  Attenuation of radiation- and chemoradiation-induced mucositis using gamma-D-glutamyl-L-tryptophan (SCV-07).

Authors:  B Watkins; K Pouliot; E Fey; C Tuthill; S Sonis
Journal:  Oral Dis       Date:  2010-10       Impact factor: 3.511

2.  A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain.

Authors:  Bruno Georg Oertel; Mattias Kettner; Klaus Scholich; Christoph Renné; Bianca Roskam; Gerd Geisslinger; Peter Harald Schmidt; Jörn Lötsch
Journal:  J Biol Chem       Date:  2008-12-30       Impact factor: 5.157

3.  A randomized, double-blind, placebo-controlled trial of misoprostol for oral mucositis secondary to high-dose chemotherapy.

Authors:  Rajesh V Lalla; Gary B Gordon; Mark Schubert; Sol Silverman; Mark Hutten; Stephen T Sonis; Francis LeVeque; Douglas E Peterson
Journal:  Support Care Cancer       Date:  2011-10-01       Impact factor: 3.603

4.  Topical transforming growth factor-beta3 in the prevention or alleviation of chemotherapy-induced oral mucositis in patients with lymphomas or solid tumors.

Authors:  M C Foncuberta; P J Cagnoni; C H Brandts; R Mandanas; K Fields; H G Derigs; E Reed; S T Sonis; J Fay; F LeVeque; P Pouillart; H Schrezenmeier; R Emmons; E Thiel
Journal:  J Immunother       Date:  2001 Jul-Aug       Impact factor: 4.456

Review 5.  Peripheral glutamate signaling in head and neck areas.

Authors:  Helga Susanne Haas; Alexander Linecker; Roswitha Pfragner; Anton Sadjak
Journal:  Head Neck       Date:  2010-11       Impact factor: 3.147

6.  Transforming growth factor-B3 protects murine small intestinal crypt stem cells and animal survival after irradiation, possibly by reducing stem-cell cycling.

Authors:  D Booth; J D Haley; A M Bruskin; C S Potten
Journal:  Int J Cancer       Date:  2000-04-01       Impact factor: 7.396

7.  Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality.

Authors:  C L Farrell; J V Bready; K L Rex; J N Chen; C R DiPalma; K L Whitcomb; S Yin; D C Hill; B Wiemann; C O Starnes; A M Havill; Z N Lu; S L Aukerman; G F Pierce; A Thomason; C S Potten; T R Ulich; D L Lacey
Journal:  Cancer Res       Date:  1998-03-01       Impact factor: 12.701

8.  Endothelin-A receptor antagonism attenuates carcinoma-induced pain through opioids in mice.

Authors:  Phuong N Quang; Brian L Schmidt
Journal:  J Pain       Date:  2010-01-13       Impact factor: 5.820

9.  Basic fibroblast growth factor and epidermal growth factor reverse impaired ulcer healing of the rabbit oral mucosa.

Authors:  Kenji Fujisawa; Youji Miyamoto; Masaru Nagayama
Journal:  J Oral Pathol Med       Date:  2003-07       Impact factor: 4.253

Review 10.  A human trial of HSV-mediated gene transfer for the treatment of chronic pain.

Authors:  D Wolfe; M Mata; D J Fink
Journal:  Gene Ther       Date:  2009-02-26       Impact factor: 5.250

View more
  21 in total

1.  Modulation of radiation-induced oral mucositis by pentoxifylline: preclinical studies.

Authors:  Sylvia Gruber; Margret Schmidt; Eva Bozsaky; Kathrin Wolfram; Julia Haagen; Bettina Habelt; Martin Puttrich; Wolfgang Dörr
Journal:  Strahlenther Onkol       Date:  2014-10-29       Impact factor: 3.621

Review 2.  Cancer and Referred Facial Pain.

Authors:  Marcela Romero-Reyes; Antonia Teruel; Yi Ye
Journal:  Curr Pain Headache Rep       Date:  2015-08

3.  Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: children and adolescents.

Authors:  Juliana Moura Nabarrete; Andrea Z Pereira; Adriana Garófolo; Adriana Seber; Angela Mandelli Venancio; Carlos Eduardo Setanni Grecco; Carmem Maria Sales Bonfim; Claudia Harumi Nakamura; Daieni Fernandes; Denise Johnsson Campos; Fernanda Luisa Ceragioli Oliveira; Flávia Krüger Cousseiro; Flávia Feijó Panico Rossi; Jocemara Gurmini; Karina Helena Canton Viani; Luciana Fernandes Guterres; Luiz Fernando Alves Lima Mantovani; Luiz Guilherme Darrigo Junior; Maria Isabel Brandão Pires E Albuquerque; Melina Brumatti; Mirella Aparecida Neves; Natália Duran; Neysimelia Costa Villela; Victor Gottardello Zecchin; Juliana Folloni Fernandes
Journal:  Einstein (Sao Paulo)       Date:  2021-12-10

4.  Neurotrophin Pathway Receptors NGFR and TrkA Control Perineural Invasion, Metastasis, and Pain in Oral Cancer.

Authors:  Coleen Doan; Bradley E Aouizerat; Yi Ye; Dongmin Dang; Kesava Asam; Aditi Bhattacharya; Timothy Howard; Yogin K Patel; Dan T Viet; Johnny D Figueroa; Jiang F Zhong; Carissa M Thomas; Anthony B Morlandt; Gary Yu; Nicholas F Callahan; Clint T Allen; Anupama Grandhi; Alan S Herford; Paul C Walker; Khanh Nguyen; Stephanie C Kidd; Steve C Lee; Jared C Inman; Jason M Slater; Chi T Viet
Journal:  Adv Biol (Weinh)       Date:  2022-08-04

Review 5.  Pathophysiology of Radiation-Induced Dysphagia in Head and Neck Cancer.

Authors:  Suzanne N King; Neal E Dunlap; Paul A Tennant; Teresa Pitts
Journal:  Dysphagia       Date:  2016-04-20       Impact factor: 3.438

6.  Modulation of radiation-induced oral mucositis by thalidomide : Preclinical studies.

Authors:  Katharina Frings; Sylvia Gruber; Peter Kuess; Miriam Kleiter; Wolfgang Dörr
Journal:  Strahlenther Onkol       Date:  2016-06-09       Impact factor: 3.621

7.  The usefulness of the Electronic Patient Visit Assessment (ePVA)© as a clinical support tool for real-time interventions in head and neck cancer.

Authors:  Janet H Van Cleave; Mei R Fu; Antonia V Bennett; Catherine Concert; Ann Riccobene; Anh Tran; Allison Most; Maria Kamberi; Jacqueline Mojica; Justin Savitski; Elise Kusche; Mark S Persky; Zujun Li; Adam S Jacobson; Kenneth S Hu; Michael J Persky; Eva Liang; Patricia M Corby; Brian L Egleston
Journal:  Mhealth       Date:  2021-01-20

8.  James Logan Prize Essay. The challenges of cancer pain assessment.

Authors:  Katherine McCracken
Journal:  Ulster Med J       Date:  2015-01

Review 9.  Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice.

Authors:  Douglas E Peterson; Joyce A O'Shaughnessy; Hope S Rugo; Sharon Elad; Mark M Schubert; Chi T Viet; Cynthia Campbell-Baird; Jan Hronek; Virginia Seery; Josephine Divers; John Glaspy; Brian L Schmidt; Timothy F Meiller
Journal:  Cancer Med       Date:  2016-06-23       Impact factor: 4.452

Review 10.  Differential Superiority of Heavy Charged-Particle Irradiation to X-Rays: Studies on Biological Effectiveness and Side Effect Mechanisms in Multicellular Tumor and Normal Tissue Models.

Authors:  Stefan Walenta; Wolfgang Mueller-Klieser
Journal:  Front Oncol       Date:  2016-02-25       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.